Butamidine | 124076-61-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: Butamidine
• 英文别名: 4-[4-(4-carbamimidoylphenoxy)butoxy]benzenecarboximidamide
• CAS: 124076-61-5
• 化学式: C₁₈H₂₂N₄O₂
• 分子量: 326.398
• InChiKey: KXHZWUUTWSKONE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  24
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  118
• 氢给体数：
  4
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  4,4'-(butane-1,4-diylbis(oxy))dibenzonitrile 在 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 为溶剂， 以47.8%的产率得到Butamidine
  参考文献：
  名称：

  Discovery of decamidine as a new and potent PRMT1 inhibitor

  摘要：

  这份报告介绍了十甲胺作为蛋白质精氨酸甲基转移酶1（PRMT1）的有效抑制剂的合成和评价。

  DOI：

  10.1039/c6md00573j

文献信息

• Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients
  申请人：Rogers D. Robin

  公开号：US20070093462A1

  公开（公告）日：2007-04-26

  Disclosed are ionic liquids and methods of preparing ionic liquid compositions of active pharmaceutical, biological, nutritional, and energetic ingredients. Also disclosed are methods of using the compositions described herein to overcome polymorphism, overcome solubility and delivery problems, to control release rates, add functionality, enhance efficacy (synergy), and improve ease of use and manufacture.

  揭示了离子液体及制备活性药物、生物、营养和能量成分的离子液体组合物的方法。还揭示了利用本文描述的组合物的方法，以克服多型性、克服溶解度和输送问题、控制释放速率、增加功能性、增强功效（协同作用）以及改善易用性和制造工艺。
• Amidine derivatives for treating amyloidosis
  申请人：Chalifour J. Robert

  公开号：US20070021483A1

  公开（公告）日：2007-01-25

  The present invention relates to the use of amidine compounds in the treatment of amyloid-related diseases. In particular, the invention relates to a method of treating or preventing an amyloid-related disease in a subject comprising administering to the subject a therapeutic amount of an amidine compound. Among the compounds for use according to the invention are those according to the following Formula, such that, when administered, amyloid fibril formation, neurodegeneration, or cellular toxicity is reduced or inhibited:

  本发明涉及在治疗与淀粉样相关疾病中使用氨基脲类化合物。特别地，本发明涉及一种治疗或预防受试者淀粉样相关疾病的方法，包括向受试者施用治疗剂量的氨基脲类化合物。根据本发明使用的化合物包括以下化学式的化合物，当施用时，可减少或抑制淀粉样纤维形成、神经退行性或细胞毒性：
• Multi-Functional Ionic Liquid Compositions for Overcoming Polymorphism and Imparting Improved Properties for Active Pharmaceutical, Biological, Nutritional, and Energetic Ingredients
  申请人：Rogers Robin D.

  公开号：US20120264605A1

  公开（公告）日：2012-10-18

  Disclosed are ionic liquids and methods of preparing ionic liquid compositions of active pharmaceutical, biological, nutritional, and energetic ingredients. Also disclosed are methods of using the compositions described herein to overcome polymorphism, overcome solubility and delivery problems, to control release rates, add functionality, enhance efficacy (synergy), and improve ease of use and manufacture.

  本发明涉及离子液体和制备含有活性制药、生物、营养和能量成分的离子液体组合物的方法。同时，本发明还涉及使用所述组合物的方法，以克服多晶性、克服溶解度和输送问题、控制释放速率、增加功能、增强功效（协同作用）和改善使用和制造的便利性。
• Benzamidoxime prodrugs as antipneumocystic agents
  申请人：THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL

  公开号：EP1561463A2

  公开（公告）日：2005-08-10

  A compound of Formula II: wherein: R1 and R2are each independently selected from the group consisting of H, loweralkyl, oxyalkyl, alkoxyalkyl, cycloalkyl, aryl, hydroxyalkyl, aminoalkyl or alkylaminoalkyl; R3is H, loweralkyl, oxyalkyl, alkoxyalkyl, hydroxyalkyl, cycloalkyl, aryl, aminoalkyl, alkylaminoalkyl or halogen; R4 is-OY, or R1 and R4 together represent and A is a heterocyclic aromatic group.

  式 II 的化合物： 其中 R1 和 R2 各自独立地选自 H、低级烷基、氧基烷基、烷氧基烷基、环烷基、芳基、羟基烷基、氨基烷基或烷基氨基烷基组成的组； R3 是 H、低级烷基、氧代烷基、烷氧基烷基、羟基烷基、环烷基、芳基、氨基烷基、烷基氨基烷基或卤素； R4 是-OY，或 R1 和 R4 共同代表 和 A 是杂环芳基。
• Analogs of 1,5-bis(4-amidinophenoxy)pentane (pentamidine) in the treatment of experimental Pneumocystis carinii pneumonia
  作者：Richard R. Tidwell、Susan Kilgore Jones、J. Dieter Geratz、Kwasi A. Ohemeng、Michael Cory、James Edwin Hall

  DOI：10.1021/jm00166a026

  日期：1990.4

  A series of 33 analogues of the anti-Pneumocystis carinii drug 1,5-bis(4-amidinophenoxy)pentane (pentamidine) was synthesized for screening against a rat model of P. carinii pneumonia (PCP). Twenty-five of the compounds showed efficacy against PCP when compared to a saline-treated control group. Two compounds, 1,4-bis(4-amidinophenoxy)butane (butamidine, 6) and 1,3-bis(4-amidino-2-methoxyphenoxy)propane (DAMP, 16), were statistically more effective than the parent drug in treating PCP in the rat model of infection. In addition to their activity against PCP, the compounds were also evaluated for antitrypsin activity, ability to inhibit thymidylate synthetase, affinity for DNA, and toxicity. No correlation was observed between the tested molecular interactions of the diamidines and their effectiveness against PCP.